The injection can be administered at any time on the scheduled day, and patients do not need to inject at the same time each weekonly the same day matters for maintaining steady-state drug levels
A 2mg dose uses 40 units, 4mg uses 80 units, and so forth
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
Potential Risks and Considerations While BPC-157 shows enormous promise for gut healing, its important to understand the potential risksespecially since its not an FDA-approved treatment and lacks large-scale human trials